Komunikaty PR

Chloe Hodge’s A Sea of Secrets Continues the Terrulian Trials Urban Fantasy Saga with Magic and Intrigue: OUT NOW

2025-06-16  |  20:55:04

A steamy, high-stakes urban fantasy, A Sea of Secrets delivers magic, murder, and heart-racing romance.

LOS ANGELES, CA, UNITED STATES, June 16, 2025 /EINPresswire.com/ -- Award-winning author Chloe Hodge and Rebecca Camm have released the highly anticipated third installment in their Terrulian Trials series, A Sea of Secrets, a steamy, suspenseful urban fantasy that plunges readers deeper into a world of magic, mystery, and deadly trials.

To purchase copies of Hodge’s magical books, click here: https://www.chloehodge.com/

"The imagination is like a wild playground where anything is possible. I love diving into new worlds that stretch beyond the limits of reality. Through my books, I want readers to feel they can become anyone, be anything, and explore places they’ve never even dreamed of. That’s the magic of storytelling: it’s a passport to endless adventure and self-discovery," Hodge exclaims.

In A Sea of Secrets, death stalks the Halls of Ascension as Fallon Auger, daughter of House Jupiter, races to capture a murderer who slipped through their grasp, with one final trial standing between her and freedom for Terrulia. Amidst dark magic, blood, and betrayal, she leans on four fiercely loyal allies who hold her bleeding heart together, ready to face monsters and enemies alike in a relentless pursuit of justice and revenge.

The Terrulian Trials series is a unique blend of urban fantasy and Why Choose storytelling, featuring multiple first-person points of view, enemies-to-lovers romances, and a high-stakes academy setting. Fans of Zodiac Academy, The Hunger Games, and The Bonds That Tie will find a thrilling mix of humor, brutality, and steamy passion in this bold and addictive series.

The series begins with A Sky of Storms, where the daughter of House Jupiter fights to claim the throne in a deadly competition filled with political intrigue and romantic tension. A Forest of Fire raises the stakes with murder, blackmail, and firestorm disasters. Now, A Sea of Secrets brings the action to a fever pitch, setting the stage for an unforgettable climax.

"Writing The Terrulian Trials has been an incredible journey of crafting a world where magic, loyalty, and betrayal collide," says Chloe Hodge. "With A Sea of Secrets, I wanted to push the stakes even higher and give readers a finale full of emotion, action, and the steamy relationships they’ve come to expect."

A Sea of Secrets is now available on Amazon, Barnes & Noble, and all major book retailers. Dive into the Terrulian Trials series today to experience a world where danger lurks in every shadow, and no one is safe.

Check out all of Chloe Hodge’s unforgettable series:

The Terrulian Trials

An urban fantasy, the Why Choose series is packed with steamy romance, high-stakes academy challenges, and magic. It features multi-perspective storytelling and explores complex characters navigating loyalty, power, and identity in a brutal, thrilling world.

The Cursed Blood

A dark fantasy romance series steeped in Hungarian folklore, witches, and arranged marriage. Filled with enemies-to-lovers tension, dark magic, and dangerous stakes, it follows a witch caught between fate and desire in a fight to save her kingdom.

The Guardians of the Grove

An epic fantasy trilogy weaving together prophecy, chosen ones, and a sprawling adventure to protect multiple realms. Fans of Throne of Glass and The Lord of the Rings will enjoy this action-packed saga of war, alliances, and sacrifice.

Romancing the Realms

A collection of romantic fantasy standalones by various authors, with Chloe Hodge’s Courting the Fae Captain delivering fierce heroines, fake dating, fated mates, and high-stakes magic in a richly imagined fae world.

"For readers craving something fresh and different, A Sea of Secrets delivers a world where the unexpected is the norm and every page holds a new surprise. This summer’s hottest read is perfect for anyone looking to escape into a place where anything is possible, a must-have for every bookshelf and adventurous heart."

About Chloe Hodge

Chloe Hodge is a bestselling author known for her immersive fantasy and urban fantasy novels featuring complex characters, rich world-building, and sizzling romance. She is the co-author of the Terrulian Trials series and the bestselling Cursed Blood series, among others. Chloe’s work is beloved by fans who crave stories full of mystery, magic, and heart.

JOIN THE COVEN!
Get exclusive content, early reveals, and insider access to all the steamy drama from Chloe Hodge and Rebecca Camm: https://www.chloehodge.com/

Website: www.chloehodge.com

Amazon Author Page: https://amzn.to/4dNUsU1

Join the Community: https://bit.ly/43tUziL

Amanda Kent
Boundless Media USA
+1 313-403-5636
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze Prasowym”, których autorami są zarejestrowani użytkownicy tacy jak agencje PR, firmy czy instytucje państwowe.
Ostatnio dodane
komunikaty PR z wybranej przez Ciebie kategorii
EIN Newswire BRAK ZDJĘCIA
2025-06-17 | 03:55:06

NEXCOM EBC 370 Powers Autonomous Robotics for Industrial Applications

Highly Efficient, Edge AI Computing Delivered in a Compact New CPUThe EBC 370/EBC 370X is an AI-powered, PC-based controller designed to adapt to the most demanding conditions. Research labs use it as the main control unit for advanced robotics
EIN Newswire BRAK ZDJĘCIA
2025-06-17 | 03:55:06

The End Brain Cancer Initiative Partners with Curis to Pre-qualify for PCNSL TakeAim Lymphoma Clinical Trial

The End Brain Cancer Initiative Partners with Curis to Promote Awareness and Pre-qualify for PCNSL TakeAim Lymphoma Clinical Trial REDMOND, WA, UNITED STATES, June 16, 2025 /EINPresswire.com/ -- FOR IMMEDIATE RELEASE Contact: Dellann Elliott Mydland, 425-785-8489, Dellann@EndBrainCancer.org The End Brain Cancer Initiative Partners with Curis to Promote Awareness and Pre-qualify for PCNSL TakeAim Lymphoma Clinical Trial The End Brain Cancer Initiative (EBCI) has partnered with Curis to promote awareness and pre-qualify patients for the company’s TakeAim Lymphoma Clinical Trial (CA-4948-101) clinical trial, an open-label, dose escalation and expansion trial of Emavusertib in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/​R PCNSL) (NCT03328078). “We are proud to partner with the End Brain Cancer Initiative to help raise awareness for primary CNS lymphoma (PCNSL), a rare and challenging form of cancer non-Hodgkin lymphoma. Together, we aim to highlight the unmet medical needs of this patient community, provide relevant resources to patients and their care providers, along with increasing awareness of clinical trials,” shared the Chief Medical Officer of Curis Inc, Ahmed Hamdy, MD. “Curis is committed to developing emavusertib for the treatment of PCNSL and broader non-Hodgkin lymphoma indications.” Patients who would like to learn more about this clinical trial and see if they qualify can visit https://endbraincancer.org/curis-therapeutics/ or contact the End Brain Cancer Initiative’s Clinical Research Coordinator and Patient Navigator, Shreya Prakash, at Shreya@EndBrainCancer.org or 425-436-8688. About Curis Curis, located in Lexington, Massachusetts, is a biotechnology company focused on the development of Emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the TakeAim Leukemia Phase 1/2 study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), and as a frontline combination therapy with venetoclax and azacitidine in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to Emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at https://www.curis.com/. About the End Brain Cancer Initiative To support/donate to the End Brain Cancer Initiative’s increased access and health delivery for patients, mission, services and programs, please visit EndBrainCancer.org The End Brain Cancer Initiative (EBCI) is a 501(c)3 non-profit patient advocacy organization focused on disease education, awareness, outreach, increasing patient access and improving Standard of Care. The End Brain Cancer Initiative, formerly known as the Chris Elliott Fund (CEF), is dedicated to ensuring that all patients diagnosed with brain cancer, a brain tumor, or metastatic disease to the brain have equal access to advanced diagnostics, treatments, specialists, and clinical trial participation. We believe that IMMEDIATE ACCESS to these options provides this patient community with the best HOPE for survival and sustained quality of life. We partner with industry, patients, researchers, advocacy groups, medical teams, hospital networks and others to educate patients and their caregivers so they can have empowered conversations with their medical teams. Learn more about the End Brain Cancer Initiative or how to sponsor this annual campaign at EndBrainCancer.org. Dellann Elliott Mydland, End Brain Cancer Initiative, 425-785-8489, Dellann@EndBrainCancer.org
EIN Newswire BRAK ZDJĘCIA
2025-06-17 | 02:55:04

Uncle Sharkii Poke Bar Franchisees Honored with Multi-Unit Mastery Award

Uncle Sharkii franchisees Bruno and Jessica Picelli with the 2024 Multi-Unit Mastery Award.The award recognizes the longtime franchisees’ successful leadership and operational excellence across five Uncle Sharkii Poke Bar locations.From day

Kalendarium

Więcej ważnych informacji

Jedynka Newserii

Jedynka Newserii

Kongres Profesjonalistów Public Relations

Ochrona środowiska

Z powodu braku przejrzystego prawa branża recyklingu odkłada inwestycje. Firmy apelują o szybkie wdrożenie przepisów

Branża recyklingu stoi przed wyzwaniami związanymi z wdrożeniem systemu kaucyjnego, systemu rozszerzonej odpowiedzialności producenta i rozporządzenia PPWR. Brakuje jednak odpowiednich przepisów dostosowujących polskie prawo i realia do unijnych regulacji. W efekcie utrzymującej się niepewności prawnej między 2018 a 2023 rokiem co trzeci zakład recyklingu zamknął działalność. Wiele firm odkłada inwestycje, czekając na uregulowanie rynku. Podobna niepewność dotyczy też producentów opakowań. 

Transport

Testowanie pojazdów zautomatyzowanych wkrótce będzie możliwe. To odpowiedź na postulaty przedsiębiorców

Kończą się prace nad przepisami, które mają usprawnić prace badawcze nad pojazdami zautomatyzowanymi. Ma to być odpowiedź na postulaty przedsiębiorców, którzy wskazywali na potrzebę pilnej zmiany przepisów w zakresie testowania pojazdów autonomicznych. Obecne regulacje nie sprzyjają postępowi technologicznemu i rozwoju autonomiczności pojazdów, o czym świadczy bardzo niewielka liczba wydanych uprawnień do ich prowadzenia.

Firma

Przedsiębiorcom coraz bardziej doskwiera niestabilność i skomplikowanie przepisów podatkowych. Problemem są też niejasne ich interpretacje

Polscy przedsiębiorcy często negatywnie oceniają jakość przepisów podatkowych – wynika z raportu „Przedsiębiorcy pod lupą fiskusa 2025” przygotowanego przez firmę doradztwa podatkowego MDDP we współpracy z Konfederacją Lewiatan. Ich niepokój budzą niejednolite interpretacje przepisów i niepewność prawa podatkowego, które cały czas jest modyfikowane. Wśród kluczowych zmian w obszarze podatków, które będą dotyczyć praktycznie wszystkich przedsiębiorców, są m.in. wprowadzenie Krajowego Systemu e-Faktur czy zmiany w podatku od nieruchomości.

Partner serwisu

Instytut Monitorowania Mediów

Szkolenia

Akademia Newserii

Akademia Newserii to projekt, w ramach którego najlepsi polscy dziennikarze biznesowi, giełdowi oraz lifestylowi, a  także szkoleniowcy z wieloletnim doświadczeniem dzielą się swoją wiedzą nt. pracy z mediami.